Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Dec 15, 2014
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
Pulsed dye laser (PDL) is the gold standard treatment for port-wine stains (PWS). However, the outcomes are highly variable due to the new angiogenesis occurring after laser irradiation. Studies suggest that endothelin is involved in the neoangiogenesis that occurred after treatment of port-wine stains by PDL . The main objective of this pilot clinical trial is to evaluate the effectiveness and safety of an inhibitor of endothelin orally taken, the Bosentan, following PDL treatment. Four patients with facial port-wine stain resistant to the PDL treatment will be included. The treatment by B...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children of 7 years old and over or adults aged under 60
- • with a resistant port-wine stain after treatment by PDL will be included in this pilot study.
- • The agreement of the parents and the child or the patient alone if major will be required.
- • Subjects have to be registered to the social security.
- • An informed consent will have to be signed by the parents or the patient if of a suitable age or the patient alone if major.
- • An efficient contraception will be mandatory if the patient is female and an age to give birth.
- Exclusion criteria:
- • Hypersensitivity to the Bosentan or to one of its excipients.
- • Mild to severe liver disease corresponding to the Child-Pugh Score B or C.
- • Serum levels of ASAT and/or ALAT greater three times the upper limit of normal. - Concurrent use of cyclosporine.
- • Pregnancy.
About Centre Hospitalier Universitaire De Nice
The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nice, Alpes Maritimes, France
Patients applied
Trial Officials
PASSERON Thierry, Phd
Principal Investigator
CHU De Nice, Dermatologie, Hôpital de l'archet 151 route de st-antoine de ginestière 06200 nice
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials